# Matthew Holt

Matthew Holt is co-founder of Collaborative Sourcing, a procurement consultancy for pharmaceutical and biotechnology companies. Holt's posts discuss procurement transformation, supply-chain resilience and building stronger supplier relationships in the life-sciences industry.

- Profile: https://b2binfluencer.marketing/creators/matthew-holt/
- LinkedIn: https://www.linkedin.com/in/matthew-holt-30547b151
- LinkedIn followers: 2,848
- Topics: supply-chain
- Based on 14 dated posts, latest 2026-10-07

## Summary

They are most useful for practical thought leadership on life-sciences procurement, supplier relationships and supply-chain resilience.

- Best for: This fits a pharma services company or procurement consultancy wanting a co-authored thought-leadership series for life-sciences procurement leaders.
- Not for: This does not fit a consumer brand or general B2B software sponsor wanting high-volume short-form video.
- Check first: Ask for follower demographics and per-post engagement before setting reach expectations.

### Takeaways

- Procurement is invited late when the organisation defines it as a price-negotiation function.
- Short event meetings work better as question-and-follow-up conversations than as pitches.
- Trade-show buyers remember how suppliers answer the question they did not prepare for.

## Main ideas

- **Procurement is invited late when the organisation defines it as a price-negotiation function**: Matthew Holt argues that late involvement is usually not an accident. If procurement is understood as getting a better price on something already chosen, involving it during scoping would make no sense. By the time the specification, preferred supplier and timeline are fixed, most value has already been decided; what remains is negotiating margin on someone else's decision. Procurement is then judged on savings against a baseline it did not set. The real question is whether the organisation believes procurement contributes before the point of purchase. Otherwise, an earlier invitation just means sitting through a longer meeting.
- **Short event meetings work better as question-and-follow-up conversations than as pitches**: Matthew Holt argues that a CPHI or similar meeting is too short to waste on a pitch the other person could have read online. The outcome changes if the supplier arrives with two or three genuine questions, asks how the buyer actually decides between suppliers rather than only what they need, follows up within 48 hours with a specific reference to what was said, and resists overselling. Restraint signals that the supplier understood the buyer's situation. The point is not new marketing material; it is a plan for the conversation.
- **Trade-show buyers remember how suppliers answer the question they did not prepare for**: Exhibitors think they are evaluated on their pitch, but procurement teams remember how they respond to a specific, slightly awkward question: a capacity constraint, a past delivery miss or what happens if volume doubles unexpectedly. A polished capability deck tells the buyer what the supplier wants them to know. Confidence in that moment signals partnership potential; a scripted deflection reads as exactly that. Buyers do not expect weakness-free suppliers; they want suppliers to be honest about weaknesses because that is the version they can work with when something goes wrong.
- **Procurement transformation looks different at each company stage**: Collaborative Sourcing links its work to different life-science company stages. Established API manufacturers are building greater supply-chain resilience; growing drug manufacturers are developing procurement functions to support their ambitions; biotech startups need foundational procurement expertise. The stated aim is to move pharmaceutical supply chains from firefighting to flow. This staged view matters because the same procurement advice does not fit every company: the starting point depends on maturity and immediate risk.
- **Trust, transparency and collaboration are stated as the goal, not just a slogan**: Across the posts, Matthew Holt consistently argues that procurement should help pharmaceutical and biotechnology companies build partnerships with trust, transparency and collaboration at their heart. That frame connects the diagnostic argument about procurement's role with the practical event advice about honest answers and specific follow-up. The author descriptions and post closings present these values as a stated priority rather than a one-off theme.

## Work to read

- [Procurement is invited late because of what the organisation thinks it is for](https://www.linkedin.com/posts/matthew-holt-30547b151_supplychain-riskmanagement-biotech-activity-7508412425260695552-FLyb)
- [Trade-show exhibitors are judged on the question they did not prepare for](https://www.linkedin.com/posts/matthew-holt-30547b151_supplychain-riskmanagement-biotech-activity-7510300081905078273-QxgO)
- [A CPHI meeting is wasted if it is only a pitch](https://www.linkedin.com/posts/matthew-holt-30547b151_supplychain-riskmanagement-biotech-activity-7510950154477142016-_JkQ)
- [Client work across the UK, Spain and Italy, and the shift from firefighting to flow](https://www.linkedin.com/posts/matthew-holt-30547b151_cphimilan-pharma-procurement-activity-7509160447120531456-xhX0)

## Brand relationships

- **Collaborative Sourcing** (owned_business)
- **QYOBO** (mention)
- **CPHI Milan** (mention)

## Partnerships

Matthew Holt's posts describe a consultancy business rather than an advertised sponsorship offer. They are co-founder of Collaborative Sourcing, a life-sciences procurement consultancy, and the posts work as outreach for that business: they describe client work across the UK, Spain and Italy, invite readers to drop a message and connect or follow the link in the bio, and point to a monthly newsletter, The Collaborative Source, in the Featured section. The posts include no packages, rates, deliverables, audience guarantees, deadlines or editorial guidelines, and identify no official partnership or sponsorship inquiry page. They post alongside named colleagues, mention travelling with Graham Phillipson on client and event trips, and appear at industry events such as CPHI Milan, so a co-authored series could sit naturally beside event-driven content. Before proceeding, ask whether paid collaborations are accepted, who holds commercial or editorial sign-off, and what packages, rates, deliverables and guidelines apply. The realistic entry point for a co-authored thought-leadership series is a direct approach to Holt and Collaborative Sourcing.

## Alternatives

- Oscar Vega: Choose Oscar Vega when the series needs to move from procurement's internal standing to the sourcing decisions behind it: whether to shift manufacturing out of China, how to assess a China+1 strategy when final assembly moves but components and tooling stay, and why nearshoring to Mexico should be judged on proximity, lead times, and capability rather than labor arbitrage alone. Their posts argue that changing a supplier's address does not remove concentration risk, and that procurement should map beyond tier 1 to critical components, tooling, raw materials, and single-source dependencies. This is a better base than Matthew Holt's material for supply-chain strategy leaders weighing footprint and resilience, or for campaigns seeking concrete frameworks for sourcing model design rather than procurement's organisational role.
- Lavine Hemlani: Choose Lavine Hemlani when the series targets investors, sovereign funds, or national biotech programmes rather than procurement teams. Their posts analyse the UAE's attempt to build capital, regulation, manufacturing, and genomic data under one roof; note that drug discovery is now Mubadala's largest investment sector, ahead of software and fintech; and argue that biotech's bottleneck is everything around the science. This is a better basis for campaigns that position procurement within a larger ecosystem-building story, reach leaders in Gulf biotech investment and policy, or connect sourcing practice to national industrial strategy and capital allocation.
- Dan Lewis: Choose Dan Lewis when the series needs a regular news-and-update rhythm and a wider life-sciences manufacturing lens. Their posts cover industry developments such as licensing deals, regulatory turnover, restructuring, and a top-selling drug milestone. They also write about digital manufacturing, automation, CQV, and operational readiness when an acquisition brings automation expertise into a project-delivery platform. This is a better fit for campaigns built around frequent, broad updates, sponsors seeking to reach manufacturing, CQV, and project-delivery audiences in life sciences, or series showing how procurement works alongside engineering, quality, and operations in facility and product delivery.

---
AI-assisted summary of public posts. Audience demographics are not available. Engagement appears only where we checked recent posts. Method: https://b2binfluencer.marketing/methodology/